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Metastatic cancers, including malignant cutaneous melanoma, have remained an incurable disease 
for most patients. Major advancements in the fields of targeted therapies and immunotherapies 
have brought some breakthrough to successfully eradicate metastatic melanoma. However, a 
large fraction of patients suffer from intrinsic or acquired resistances to these therapeutics and 
eventually display progressing disease (Hugo et al., 2015; Sharma et al., 2017; Sun et al., 2014). 
For many cancers, it is thought that intratumoral heterogeneity fosters tumor evolution. Tumor 
heterogeneity may arise from genetic aberrations as well as epigenetic mechanisms, such as DNA 
methylation or post-translational modifications of histones, both of which can heritably perturb 
gene expression (McGranahan and Swanton, 2017). Conceivably, during cancer therapies, 
resistances can emerge through an evolutionary process that selects pre-existing genetic or 
epigenetic sub-clones, the latter of which could consist of cancer stem-like cells. However, in an 
alternative scenario, cancer cells adaptively gain resistance mechanisms through either acquiring 
further genetic alterations or rewiring of the epigenome. Of note, both selection of resistant tumor 
sub-clones as well as plastic tumor cell behavior may be supported or even instructed by the 
microenvironment, especially the immune compartment (McGranahan and Swanton, 2017; 
Sharma et al., 2017). 
In recent years, small molecules targeting the MAPK signaling pathway, which is aberrantly 
activated in the majority of cutaneous melanomas, have emerged as therapies; for instance, the 
drug Vemurafenib is used to block the oncogenic activity of BRAFV600E. Comparing paired tumor 
biopsies before and after relapse to MAPK-blocking therapy revealed transcriptomic and 
underlying epigenetic alterations to be most recurrent, while de novo mutations were sparse 
(Hugo et al., 2015). Moreover, immunotherapies re-triggering cytotoxic T cells to eliminate 
tumor cells have recently stepped into the spotlight as promising melanoma treatments; 
Nivolumab, for instance, is a clinically applied antibody that blocks the negative immune 
checkpoint receptor PD-1 on T cells. Interestingly, similar to MAPK-blocking therapy, 
transcriptomic rather than genetic features define responses to anti-PD-1 immunotherapy (Sharma 
et al., 2017). Thus, apart from genetic perturbations, transcriptional changes and epigenomic 
rewiring appear to represent paradigm responses of melanoma cells to therapy. However, the data 
substantiating this idea have been gathered from bulk DNA and RNA sequencing. Hence, 
whether the observed transcriptional adaptations are a result of selecting epigenetically pre-
defined sub-clones or of true tumor cell plasticity has remained unclear. 
To shed light on this matter, Shaffer et al. elegantly took advantage of Luria and Delbrück’s 
“fluctuation analysis”, a method that was originally developed to study bacteria population 
heterogeneity versus mutation acquisition during gain of resistance to viral infections. In 
particular, the distribution of Vemurafenib-resistant clones emerging from a genetically 
homogeneous melanoma cell population was carefully analyzed. The data rejected the hypothesis 
that melanoma cells accumulate further mutations that would provide these cells with a selective 
advantage to acquire Vemurafenib resistance. To the contrary, the data strongly supported the 
hypothesis that any of the cells were capable of developing resistance to Vemurafenib, in favor of 
a cellular plasticity model. These findings are in agreement with the above-mentioned 
observations made in melanoma patients, which also found transcriptional and epigenetic changes 
to dominate resistance mechanisms (Hugo et al., 2015; Sharma et al., 2017; Sun et al., 2014). 
Bulk RNA sequencing comparing melanoma cell cultures before and after Vemurafenib 
resistance then identified a differentially expressed set of genes, among which were AXL, EGFR, 
JUN, LOXL2, NGFR (CD271, p75NTR), and WNT5A. Importantly, all of these genes have 
previously been linked to both MAPK-targeted therapy resistance (Hugo et al., 2015; Sun et al., 
2014) as well as inflammation, adoptive T cell transfer, or immunotherapy-induced melanoma 
immune escape (Hölzel and Tüting, 2016; Sharma et al., 2017; Zingg et al., 2017). Expression of 
aforementioned genes was low but not absent in cell cultures prior to Vemurafenib treatment. 
Therefore, Shaffer et al. screened single cells for the expression of resistance genes using single-
molecule RNA FISH and found a population of rare cells expressing these genes before drug 
exposure. When FACS-separating resistance marker-positive cells from marker-negative cells 
(e.g. NGFR+ versus NGFR–), marker-positive cells were more likely to establish resistance upon 
Vemurafenib treatment. Notably, marker-negative cells were also capable to give rise to resistant 
colonies, though with a marginal frequency. Without exposure to Vemurafenib, however, 
resistance marker-positive cells lost resistance gene expression over time. Importantly, ATAC 
sequencing of marker-positive, pre-resistant cells revealed only little changes in chromatin 
accessibility in comparison to marker-negative, non-resistant cells. Conversely, cells underwent 
global chromatin rearrangements during acquisition of stable resistance, which also affected loci 
of resistance genes, such as EGFR. Moreover, promoters displaying chromatin compaction during 
resistance acquisition frequently shared a binding motif for SOX10, a melanocyte lineage 
transcription factor previously linked to Vemurafenib therapy resistance (Sun et al., 2014). In 
contrast, open chromatin regions were enriched for binding motives of transcription factors (e.g. 
AP-1, TEAD) regulating melanoma epithelial-mesenchymal transition (EMT) and invasion. Thus, 
a genetically homogeneous melanoma cell population contains cells that sporadically upregulate 
resistance genes, which renders these cells temporally pre-resistant. However, during 
Vemurafenib drug exposure, this poised resistance state becomes epigenetically engraved, 
resulting in stably reprogrammed resistant cells (Figure 1). 
Shaffer et al. also found rare resistance marker-positive cells in human melanoma biopsies by 
taking advantage of both histological analyses and single-cell RNA sequencing data. However, in 
contrast to a controlled in vitro cell culture setup, cutaneous melanomas are genetically highly 
heterogeneous (McGranahan and Swanton, 2017). Thus, apart from reflecting sporadic in vivo 
gene expression of resistance genes, rare resistance marker-positive cells could, in principle, also 
belong to genetically distinct sub-populations. In murine melanoma models, adoptive T cell 
transfer and immunotherapies provoke tumor cell dedifferentiation, which includes epigenetic 
silencing of Sox10 and upregulation of resistance genes, such as Ngfr (Hölzel and Tüting, 2016; 
Zingg et al., 2017). Interestingly, this is dependent on the histone methyltransferase Ezh2, thus 
underpinning the relevance of adaptive epigenetic regulation, rather than clonal selection, for 
resistance acquisition to therapy (Zingg et al., 2017). Whether rare, pre-resistant cells, possibly 
with high Ezh2 activity, are also the dominant cell population to escape anti-tumor immunity, 
remains to be clarified. 
Several of the resistance genes described by Shaffer et al. are well-established markers of 
melanoma dedifferentiation, stemness, and EMT. Interestingly, in murine melanoma, anti-tumor 
immunity and inflammation not only provoke Ngfr expression and melanoma stemness, but also 
metastatic spread (Hölzel and Tüting, 2016). Thus, it is plausible that the mechanism of poised 
resistance gene expression identified by Shaffer et al. not only renders melanoma effective in 
responding to targeted therapies and immunotherapy-induced immune pressure, but might also be 
implicated in EMT and metastasis formation in untreated patients.  
Figure 1 
Human melanoma cells sporadically upregulate genes (e.g. AXL, EGFR, and NGFR) that have 
previously been linked to dedifferentiation, stemness, and EMT. Upon exposure to Vemurafenib 
melanoma therapy, cells temporally expressing such genes are more likely to develop 
Vemurafenib resistance as compared to cells negative for these genes. Therefore, sporadic 
expression of these genes renders melanoma cells pre-resistant to Vemurafenib. During resistance 
acquisition, global chromatin rearrangements, which include repression of SOX10-regulated 
genes and activation of dedifferentiation genes, then epigenetically stabilize the poised pre-
resistant state resulting in stably reprogrammed resistant cells. The melanoma pre-resistance 
plasticity found by Shaffer et al. could conceivably be relevant for tumor immune responses as 
well as formation of metastasis. 
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